[{"address1": "41 Ninth Avenue", "address2": "14th Floor", "city": "New York", "state": "NY", "zip": "10001", "country": "United States", "phone": "646 661 7661", "fax": "646 661 4027", "website": "https://www.ovidrx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.", "fullTimeEmployees": 25, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.", "age": 71, "title": "CEO & Chairman", "yearBorn": 1953, "fiscalYear": 2023, "totalPay": 1030026, "exercisedValue": 0, "unexercisedValue": 671250}, {"maxAge": 1, "name": "Mr. Jeffrey A. Rona", "age": 56, "title": "Chief Business and Financial Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 761235, "exercisedValue": 0, "unexercisedValue": 104909}, {"maxAge": 1, "name": "Ms. Meg  Alexander", "title": "President & COO", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Dirk  Haasner", "age": 59, "title": "Senior Vice President of Global Manufacturing & CMC QA", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 416952, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Julia  Tsai Ph.D.", "age": 49, "title": "Senior Vice President of Clinical Development", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Toshiya  Nishi D.V.M.", "title": "Head of Epilepsy Research", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Zhong  Zhong Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tom  Parry", "title": "Vice President of Research and Early Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Garret  Bonney", "title": "Investor Relations Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 8, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.567, "open": 0.57, "dayLow": 0.5685, "dayHigh": 0.6488, "regularMarketPreviousClose": 0.567, "regularMarketOpen": 0.57, "regularMarketDayLow": 0.5685, "regularMarketDayHigh": 0.6488, "payoutRatio": 0.0, "beta": 0.296, "forwardPE": -1.5833334, "volume": 548893, "regularMarketVolume": 548879, "averageVolume": 373854, "averageVolume10days": 391190, "averageDailyVolume10Day": 391190, "bid": 0.6069, "ask": 0.6275, "bidSize": 3, "askSize": 3, "marketCap": 43848616, "fiftyTwoWeekLow": 0.56, "fiftyTwoWeekHigh": 3.791, "priceToSalesTrailing12Months": 69.41422, "fiftyDayAverage": 0.83224, "twoHundredDayAverage": 1.31109, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -7374406, "profitMargins": 0.0, "floatShares": 50571806, "sharesOutstanding": 71009904, "sharesShort": 883735, "sharesShortPriorMonth": 692039, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0124, "heldPercentInsiders": 0.15899, "heldPercentInstitutions": 0.57729, "shortRatio": 1.83, "shortPercentOfFloat": 0.0150999995, "impliedSharesOutstanding": 71009904, "bookValue": 1.074, "priceToBook": 0.57495344, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -32501960, "trailingEps": -0.46, "forwardEps": -0.39, "enterpriseToRevenue": -11.674, "enterpriseToEbitda": 0.113, "52WeekChange": -0.84675676, "SandP52WeekChange": 0.2021538, "quoteType": "EQUITY", "currentPrice": 0.6175, "targetHighPrice": 5.0, "targetLowPrice": 1.3, "targetMeanPrice": 3.38333, "targetMedianPrice": 3.5, "recommendationKey": "none", "numberOfAnalystOpinions": 6, "totalCash": 62712000, "totalCashPerShare": 0.883, "ebitda": -65058180, "totalDebt": 15075000, "quickRatio": 5.392, "currentRatio": 5.66, "totalRevenue": 631695, "debtToEquity": 19.76, "revenuePerShare": 0.009, "returnOnAssets": -0.36043, "returnOnEquity": -0.36605, "grossProfits": 631695, "freeCashflow": -28366136, "operatingCashflow": -57858924, "revenueGrowth": 0.587, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -76.45087, "financialCurrency": "USD", "symbol": "OVID", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Ovid Therapeutics Inc.", "longName": "Ovid Therapeutics Inc.", "corporateActions": [], "regularMarketTime": 1740171551, "regularMarketChangePercent": 8.906532, "regularMarketPrice": 0.6175, "marketState": "REGULAR", "exchange": "NMS", "messageBoardId": "finmb_288870432", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "earningsTimestampStart": 1741267800, "earningsTimestampEnd": 1741613400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.46, "epsForward": -0.39, "epsCurrentYear": -0.40781, "priceEpsCurrentYear": -1.5141855, "fiftyDayAverageChange": -0.21473998, "fiftyDayAverageChangePercent": -0.2580265, "twoHundredDayAverageChange": -0.69359, "twoHundredDayAverageChangePercent": -0.5290178, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1493991000000, "regularMarketChange": 0.050500035, "regularMarketDayRange": "0.5685 - 0.6488", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 373854, "fiftyTwoWeekLowChange": 0.057500005, "fiftyTwoWeekLowChangePercent": 0.10267858, "fiftyTwoWeekRange": "0.56 - 3.791", "fiftyTwoWeekHighChange": -3.1734998, "fiftyTwoWeekHighChangePercent": -0.8371142, "fiftyTwoWeekChangePercent": -84.675674, "displayName": "Ovid Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-02-21"}]